Wanbury Limited – Investor Presentation Summary
Key Operational Highlights
- API business revenue: ₹309 crore in H1FY27 (FY26 full year: ₹574 crore)
- Formulations business revenue: ₹39 crore in H1FY27 (FY26 full year: ₹76 crore)
- 25% capacity increase in Metformin and 20% in Sertraline over last 3 years through de-bottlenecking
- 300+ field force and 30,000+ doctors engaged in formulations business
- 2 USFDA approved API facilities with 386 KL cumulative reactor capacity
Key drivers of operational performance: De-bottlenecking projects, production scaleup, efficient procurement practices, technical savings
Segment-wise Performance
- API Segment: ₹309 crore revenue in H1FY27, focused on regulated markets (EU, Brazil, US)
- Formulations Segment: ₹39 crore revenue in H1FY27, 10+ active brands in acute therapy
Explanation of significant changes in segment performance: API business remains dominant contributor (89% of total revenue), formulations business achieved break-even profitability in FY26
Financial Highlights
Revenue: ₹182.91 crore (Q2FY27), ₹348.49 crore (H1FY27)
EBITDA: ₹26.21 crore (Q2FY27), ₹42.81 crore (H1FY27)
PAT: ₹11.88 crore (Q2FY27), ₹15.13 crore (H1FY27)
EPS: ₹3.40 (Q2FY27), ₹4.33 (H1FY27)
Margins: Gross Margin 54.18% (Q2FY27), EBITDA Margin 14.33% (Q2FY27), PAT Margin 6.50% (Q2FY27)
YoY/QoQ comparison: Q2 revenue up 14% YoY and 10% QoQ; H1 revenue up 8% YoY
Drivers of financial performance: Higher revenue growth, partial pass-through of increased raw material costs, lower finance costs
Key Risks: Elevated prices of solvents and crude oil linked raw materials, regulatory compliance requirements
Geographical Revenue Split
Domestic vs Export/Regional Revenue: 80%+ export top line with emphasis on developed markets
Balance Sheet Snapshot
Net Debt/Equity: Debt/EBITDA ratio of ~2X
Reserves: ₹109.51 crore (FY26)
Current Assets/Liabilities: Current Assets ₹238.56 crore, Current Liabilities ₹201.04 crore (FY26)
Working Capital/Leverage Metrics: Trade Receivables ₹143.27 crore, Inventories ₹50.63 crore (FY26)
Financial Health Insights: Strong operational turnaround, reduced debt burden, healthy internal accruals
Capex & Cash Flow Health
Capital Expenditure: ₹48 crore modernized facilities (FY25)
Free Cash Flow: Not Specified
Operating Cash Flow: ₹31.53 crore (FY26)
Net Debt Movement: ~75% debt reduction from peak obligation of ~₹700 crore
Investment Rationale: Brownfield expansion, operational scale-up, borrowing cost optimization
Strategic & R&D Initiatives
Investments in Innovation: 1.5 MW solar energy project at Satara, pipeline of 4 molecules commercialization each year beginning FY27
Expected impact on growth: New API launches expected to contribute from end of current financial year
Strategic Rationale: Expanding into regulated markets (US, EU, Brazil), building niche profitable API business
Industry Trends & Business Environment
Macro/Industry Trends: West Asia crisis impacting raw material prices, regulatory requirements in developed markets
Impact on Company: Elevated input costs affecting margins, requiring price pass-through to customers
Management Commentary & Growth Outlook
Strategic Outlook: Expect better performance on both topline and profitability in second half of the year
FY Guidance: Complete recovery of margins within existing portfolio and commercialization of newer products expected
Risks and Opportunities: Raw material price volatility, timing of new product commercialization, regulatory approvals